Building The Future Of Veterinary Pharmaceuticals
AI-Driven Discovery of Prescription Phytopharmaceutical Medicines for Companion Animals
Pet Pharma Holdings is developing a new class of veterinary prescription medicines using proprietary artificial intelligence and phytopharmaceutical science.
Our PolyNexis+™ discovery platform identifies novel multi-compound therapeutic formulations designed to address major unmet needs in companion animal healthcare.
Global pet care market in 2022
Global pet care market by 2030
Dogs and cats globally
Focus Areas
Why Pet Pharma?
The global veterinary healthcare industry is undergoing profound change.
Pet owners increasingly expect human-grade healthcare for their animals, while veterinary pharmaceutical companies face growing challenges including:
Resistance to existing therapies
Increasing regulatory scrutiny
Limited therapeutic innovation
Demand for safer and more sustainable medicines
Pet Pharmaceuticals is addressing these challenges through the development of clinically validated, prescription phytopharmaceuticals supported by artificial intelligence.
Our Proprietary AI Discovery Platform
PolyNexis+™ combines:
- Artificial Intelligence
- Phytochemical Science
- Drug Development Expertise
- Predictive Modelling
- Regulatory Data Management
The platform enables:
Lead Programme: Parasiticides
We’re addressing one of the largest unmet needs in veterinary medicine through novel multi-target formulations.
Pipeline Expansion
Our platform strategy enables the efficient development of multiple prescription products across high-value veterinary markets.
- Pain & Osteoarthritis
- Dermatology
- Oncology/Lymphoma
- Anxiety & Neurology
- Diabetes & Obesity
Market Opportunity
Pet Pharmaceuticals sits at the intersection of several of the fastest-growing sectors in global animal health.